Germany Antifungal Drugs Market Size & Outlook, 2023-2030
Germany antifungal drugs market, 2018-2030 (US$M)
Related Markets
Germany antifungal drugs market highlights
- The Germany antifungal drugs market generated a revenue of USD 1,078.9 million in 2023 and is expected to reach USD 1,310.4 million by 2030.
- The Germany market is expected to grow at a CAGR of 2.8% from 2024 to 2030.
- In terms of segment, azoles was the largest revenue generating drug class in 2023.
- Echinocandins is the most lucrative drug class segment registering the fastest growth during the forecast period.
Antifungal drugs market data book summary
| Market revenue in 2023 | USD 1,078.9 million |
| Market revenue in 2030 | USD 1,310.4 million |
| Growth rate | 2.8% (CAGR from 2023 to 2030) |
| Largest segment | Azoles |
| Fastest growing segment | Echinocandins |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Azoles, Echinocandins, Polyenes, Allylamines |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Bayer AG, Sanofi SA, Merck KGaA, Merck & Co Inc, GlaxoSmithKline, Abbott Laboratories, Enzon Pharmaceuticals Inc, Astellas Pharma Inc, Glenmark Pharmaceuticals |
Other key industry trends
- In terms of revenue, Germany accounted for 6.8% of the global antifungal drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany antifungal drugs market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 1,215.7 million by 2030.
Azoles was the largest segment with a revenue share of 47.48% in 2023. Horizon Databook has segmented the Germany antifungal drugs market based on azoles, echinocandins, polyenes, allylamines covering the revenue growth of each sub-segment from 2018 to 2030.
Market players in the country enter into strategies, such as partnerships and licensing agreements, to increase their product capabilities & boost the reach of their offerings. For instance, Pfizer, Inc. recently signed a licensing agreement with Basilea Pharmaceutica Ltd. for the distribution of Cresemba in European countries.
This would allow the company to launch the product in European nations, including Germany. The Federal Institute for Drugs and Medical Devices (BfArM) and the Paul Ehrlich Institute serve as Germany's Principal Regulating Bodies (PEI).
The PEI regulates Sera, vaccines, blood products, bone marrow products, tissue products, allergens, gene transfer pharmaceuticals, somatic cell therapies, xenogenic cell therapies, and genetically engineered blood components. BfArM or PEI must grant permission to all pharmaceutical items to be sold on the home market and those intended for export.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antifungal Drugs Market Scope
Antifungal Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Germany antifungal drugs market size, by drug class, 2018-2030 (US$M)
Germany Antifungal Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
